Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 10/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3231283 | 0.81 | AVPR1A (0.54) | AVPR1AHRH3AVPR2 | |
| SCHEMBL3970017 | 0.80 | HSD11B1 (0.68) | AVPR1AHSD11B1 | |
| SCHEMBL3972505 | 0.79 | HSD11B1 (0.48) | AVPR1AHSD11B1 | |
| SCHEMBL3972921 | 0.79 | HSD11B1 (0.52) | AVPR1AHSD11B1 | |
| SCHEMBL29871828 | 0.79 | AVPR1A (0.45) | AVPR1AHSD11B1 | |
| SCHEMBL3971584 | 0.78 | HSD11B1 (0.52) | AVPR1AHSD11B1 | |
| SCHEMBL23305134 | 0.74 | AAK1 (0.32) | AVPR1A | |
| SCHEMBL29990866 | 0.72 | AVPR1A (0.59) | AVPR1AHRH3AVPR2 | |
| SCHEMBL1222056 | 0.72 | AVPR1A (0.59) | AVPR1AHRH3AVPR2 | |
| SCHEMBL4407669 | 0.71 | HSD11B1 (0.65) | AVPR1AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670154-B2 | Amido compounds and their use as pharmaceuticals | INCYTE HOLDINGS CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| US-20150329561-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION | 2015-11-19 | — | — | US | disclosed |
| US-7304081-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | AVPR1A 60/4885HSD11B1 1/4885CCNC 4446/4885 |
| US-20150329561-A1 | Amido Compounds And Their Use As Pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | AVPR1A 60/4885HSD11B1 1/4885CCNC 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.